Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss

NCT06734273 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether combining a weight-loss surgery called sleeve gastrectomy with a medication called tirzepatide leads to greater weight loss in adults with obesity or obesity-related health issues.

Status Recruiting Currently enrolling participants.

Phase Early Phase 1 First exploratory testing in people.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 42 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2025-03 · est. completion 2028-09

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06734273 ↗

Description as written by the study sponsor.

This study examines whether adding tirzepatide-a medication that helps with weight loss-after sleeve gastrectomy surgery can help people lose more weight after the surgery; better improve conditions like Type 2 diabetes, high blood pressure, high cholesterol, and sleep apnea after surgery and; whether this causes more complications or side effects compared to surgery alone.

Treatments tested

Mounjaro Drug

In this study, the intervention group (n=21) are patients who will undergo sleeve gastrectomy and receive tirzepatide after surgery. Patients who were selected in this arm will undergo a 4-week dose escalation period. Starting at 6 months they will receive weekly 2.5mg doses (for 4 weeks). Afterwards, they will receive weekly 5mg doses. They will maintain this dose until 12 months after surgery.
Sleeve Gastrectomy Procedure

Subjects in both the interventional group (n=21) and the control group (n=21) will undergo sleeve gastrectomy.

Main thing measured	Weight Loss
Sponsor	Nicholas Skertich
Conditions studied	Obesity and Obesity-related Medical Conditions
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06734273 ↗